QuickVue SARS Antigen test delivers results in just ten minutes. Credit: Bill Oxford on Unsplash.

The US Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) to Quidel’s QuickVue SARS Antigen test for Covid-19 testing.

The point-of-care assay is approved for the rapid, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 using anterior nares (NS) swab samples taken by healthcare provider from people suspected of Covid-19 within five days of symptom onset.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It needs no supplemental instrumentation and can be read visually.

The QuickVue SARS Antigen test delivers results in just ten minutes and has shown excellent performance for detecting the Covid-19 virus with 96.6% PPA and 99.3% NPA when compared with PCR.

Quidel Corporation president and CEO Douglas Bryant said: “The QuickVue rapid antigen test for coronavirus leverages our proven QuickVue visually read diagnostic platform for influenza A+B to further democratise access to affordable and highly accurate Covid-19 testing across a diverse range of medical and point-of-care locations.

“The flexibility of QuickVue for meeting the urgent testing needs of everyone from school systems to rural areas and even locations without electricity gives us the opportunity to do enormous good in communities across our nation and the world.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Quidel anticipates reaching a production run rate of 600 million QuickVue tests a year by the end of next year.

In May, the company received FDA EUA for the Lyra Direct SARS-CoV-2 Assay to allow direct Covid-19 test sample processing.

In September 1999, Quidel’s QuickVue Influenza A/B Test, the first visually read lateral flow flu test, received FDA approval.

Another Quidel cartridge-based, instrument-read rapid diagnostic system for infectious disease testing, Sofia 2 makes use of fluorescent chemistry design, an intuitive graphical user interface and optics system to deliver results in 15 minutes.